Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Favipiravir,Umifenovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Glenmark's Antiviral Combination for Moderate COVID-19 Shows no Clinical Benefit
Details : Results from the “FAITH” combination trial shows that addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate COVID-19 patients. Umifenovir did not show superior clinical outcomes when added to Favipiravir...
Product Name : FabiFlu
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 10, 2020
Lead Product(s) : Favipiravir,Umifenovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir,Umifenovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Early treatment with combination therapy will be evaluated for safety and efficacy as it is emerging as an effective approach in shortening duration of virus shedding, decreasing cytokine response, and facilitating early discharge of patients.
Product Name : FabiFlu
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2020
Lead Product(s) : Favipiravir,Umifenovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable